Zobrazeno 1 - 10
of 22
pro vyhledávání: '"Minit Shah"'
Autor:
Vanita Noronha, Manali Kolkur, R ArunKumar, Supriya Adak, Vijay Patil, Nandini Menon, Minit Shah, Kumar Prabhash
Publikováno v:
Clinical Medicine Insights: Oncology, Vol 18 (2024)
Background: There is contradicting evidence on vitamin D levels and cancer mortality rates. In this study, we aimed to evaluate the impact of baseline vitamin D level on the outcome in patients with epidermal growth factor receptor (EGFR)-mutant adva
Externí odkaz:
https://doaj.org/article/686cdcb1668d44f19272c403fae304d0
Autor:
Prerana Jha, Vaishakhi Trivedi, Nandini Menon, Minit Shah, Irene A George, Rohit Mishra, Trupti Pai, Fuzail Ahmad, Venkataramanan Ramachandran, Vanita Noronha, Kumar Prabhash, Prashant Kumar
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 7, Iss 1, Pp 110-116 (2024)
Externí odkaz:
https://doaj.org/article/5ffbb472eed9486e93eefda84451a7d3
Autor:
Ajaykumar Singh, Vijay Patil, Nandini Menon, Sucheta More, Srushti Jain, Supriya Goud, Darshit Shah, Minit Shah, Kunal Jobanputra, Ahmad Ubharay
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 7, Iss 1, Pp 19-26 (2024)
Background: This was the first Phase III randomized study comparing an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor (TKI), gefitinib, to standard-of-care chemotherapy (pemetrexed + carboplatin followed by pemetrexed maintenance)
Externí odkaz:
https://doaj.org/article/f1d767b94bf449a3a69e8af61729d19e
Autor:
Jaspreet Kaur, Ajaykumar Singh, Minit Shah, Pratik Chandrani, Anuradha Chougule, Omshree Shetty, Trupti Pai, Santosh Menon, Subhash Yadav, Akhil Kapoor, B K Mishra, Amit Dutt, Vanita Noronha, Kumar Prabhash
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 6, Iss 2, Pp 288-295 (2023)
Externí odkaz:
https://doaj.org/article/093ef49f2c804ba58a9659a46250ddff
Autor:
Prerana Jha, Vaishakhi Trivedi, Rohit Mishra, Pratik Chandrani, Radhika Venkatakrishnan, Venkataramanan Ramachandran, Minit Shah, Anuradha Choughule, Kumar Prabhash, Prashant Kumar, Vanita Noronha
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 6, Iss 3, Pp 457-460 (2023)
Externí odkaz:
https://doaj.org/article/9dbe840028c748e8a0df2eb1951836eb
Autor:
Vivek K Srigadha, Kumar Prabhash, Vanita Noronha, Amit Joshi, Vijay M Patil, Nandini Menon, Ajay K Singh, Minit Shah
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 6, Iss 1, Pp 74-87 (2023)
Cabozantinib is a tyrosine kinase inhibitor that has been approved as therapy for several solid tumors, including metastatic renal cell carcinoma, hepatocellular carcinoma, and differentiated thyroid cancer. To prepare this review, we comprehensively
Externí odkaz:
https://doaj.org/article/60dbfe1f74954885a9c291f2b9902830
Autor:
Minit Shah, Vanita Noronha, Omshree Shetty, Trupti Pai, Vijay Patil, Akhil Kapoor, Nandini Menon, Ajay K Singh, Pratik Chandrani, Anuradha Chougule, Rajeev Kumar Kaushal, Subhash Yadav, Kumar Prabhash
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 6, Iss 1, Pp 94-102 (2023)
Externí odkaz:
https://doaj.org/article/d4aba08155ed4c4eba8257e1e66e9f0a
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 6, Iss 2, Pp 349-350 (2023)
Externí odkaz:
https://doaj.org/article/83fe28ce0a5740faab0ad0b18bbbde7f
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 6, Iss 3, Pp 491-492 (2023)
Externí odkaz:
https://doaj.org/article/119c94a775b243a8880eb927a8563e44
Publikováno v:
Cancer Research, Statistics, and Treatment, Vol 6, Iss 3, Pp 484-485 (2023)
Externí odkaz:
https://doaj.org/article/90883468af4741c4ab3bc351ea717104